(Q46347493)

English

Cetuximab in combination with carboplatin and docetaxel for patients with metastatic or advanced-stage nonsmall cell lung cancer: a multicenter phase 2 study

scientific article published in November 2008

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18816622

Cetuximab in combination with carboplatin and docetaxel for patients with metastatic or advanced-stage nonsmall cell lung cancer: a multicenter phase 2 study (English)

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18816622

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18816622

author name string

Marshall T Schreeder

2

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18816622

Ronald G Steis

3

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18816622

Richard A Guidice

4

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18816622

Thomas A Marsland

5

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18816622

Elizabeth H Butler

6

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18816622

Suresh S Ramalingam

7

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18816622

language of work or name

0 references

publication date

1 November 2008

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18816622

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18816622

113

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18816622

9

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18816622

2512-2517

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18816622

Cancer statistics, 2007

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23902

7 January 2021

based on heuristic

inferred from DOI database lookup

State-of-the-art chemotherapy for advanced non-small cell lung cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23902

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23902

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non--small-cell lung cancer: a Southwest Oncology Group trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23902

7 January 2021

based on heuristic

inferred from DOI database lookup

Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group--EORTC 08975.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23902

7 January 2021

based on heuristic

inferred from DOI database lookup

The EGFR as a target for anticancer therapy--focus on cetuximab

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23902

7 January 2021

based on heuristic

inferred from DOI database lookup

Targeting epidermal growth factor receptor in lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23902

7 January 2021

based on heuristic

inferred from DOI database lookup

Antibody-dependent cellular cytotoxicity mediated by cetuximab against lung cancer cell lines

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23902

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II trial of cetuximab in patients with previously treated non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23902

7 January 2021

based on heuristic

inferred from DOI database lookup

C225 antiepidermal growth factor receptor antibody enhances the efficacy of docetaxel chemoradiotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23902

7 January 2021

based on heuristic

inferred from DOI database lookup

Sequence-dependent antiproliferative effects of cytotoxic drugs and epidermal growth factor receptor inhibitors.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23902

7 January 2021

based on heuristic

inferred from DOI database lookup

Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23902

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23902

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23902

7 January 2021

based on heuristic

inferred from DOI database lookup

Carboplatin dosage: prospective evaluation of a simple formula based on renal function

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23902

7 January 2021

based on heuristic

inferred from DOI database lookup

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23902

7 January 2021

based on heuristic

inferred from DOI database lookup

Multicenter phase I/II study of cetuximab with paclitaxel and carboplatin in untreated patients with stage IV non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23902

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I/IIa study of cetuximab with gemcitabine plus carboplatin in patients with chemotherapy-naive advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23902

7 January 2021

based on heuristic

inferred from DOI database lookup

Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23902

7 January 2021

based on heuristic

inferred from DOI database lookup

Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23902

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized phase II study of gemcitabine plus cisplatin or carboplatin [corrected], with or without cetuximab, as first-line therapy for patients with advanced or metastatic non small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23902

7 January 2021

based on heuristic

inferred from DOI database lookup

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23902

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.23902

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18816622

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18816622

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46347493&oldid=2107420103"